This article is only available with a subscription for Commercial Aviation News, Operator & Airport Data. Subscribe now to ...
CNW/ - ("Takeda") is pleased to announce new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results